Maqola

IK930, a novel TEAD inhibitor, sensitizes KRAS and EGFR mutant tumors to oncogene targeted therapy

M. RajurkarIkena Oncology, Translational Research, Boston, USA;Manuel Sánchez‐MartínIkena Oncology, Translational Research, Boston, USA;D. HidalgoIkena Oncology, Translational Research, Boston, USA;N. YoungIkena Oncology, Molecular and Cellular Oncology, Boston, USA;B. AmidonIkena Oncology, Molecular and Cellular Oncology, Boston, USA;G. PunkosdyIkena Oncology, In vivo Pharmacology, Boston, USA;J. EcsedyIkena Oncology, Discovery Biology, Boston, USALiwen XuIkena Oncology, Translational Research, Boston, USA;

European Journal of Cancerjournal2022en

ABI

Annotatsiya

Annotatsiya mavjud emas.

Mavzular

Hippo pathway signaling and YAP/TAZ Cancer-related gene regulation

Identifikatorlar

DOI: 10.1016/s0959-8049(22)00906-6

Iqtiboslar va manbalar

0 ta iqtibos0 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar · Tez orada